Impact of highly active antiretroviral therapy on chronic hepatitis b serological markers among senegalese HIV co-infected children
Background: Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) causes
complex interactions. The aim of this study was to evaluate the seroprevalence and HBV evolution among
HIV coinfected children receiving highly active antiretroviral therapy (HAART).
Methods: A descriptive cross-sectional study was carried out among 252 HIV infected children enrolled in
the Hôpital d’enfants Albert Royer, Dakar, Senegal, from April 2013 to March 2015. Clinical characteristics,
immuno-virological status, alanine aminotransferase (ALT) levels, and HBV serological marker were taken
from the patients’ medical records.
Results: Overall, 7 children were HBsAg positive with a determinate prevalence rate of 2.8%. Median
age at HIV diagnosis was 3.5 years (1.3-14.4 years). According to World Health Organization (WHO)
staging, 40.1% of children were stage 4 and 25.8% were stage 3. Of the 7 HIV/HBV-co-infected children,
6 (86%) received lamivudine alone at initiation of treatment, and only one child received tenofovir
associated with emtricitabine. Overall median HAART duration treatment including lamivudine alone or
tenofovir+lamivudine (or emtricitabine) was 7.7 years (3.3-11.3). Only the two children (29%) receiving
lamivudine during follow-up had high HBV DNA load despite having good immuno-virological status.
Suppression of HBV DNA replication was achieved in 5 (71.4%) of 7 children.
Conclusion and Global Health Implication: HIV/HBV coinfection prevalence was low in our study.
HBsAg and HBeAg loss were low while suppression of HBV DNA replication was still higher on tenofovir.
Screening and monitoring HBV infection among all HIV infected children are required to direct treatment
in order to improve children HBV/HIV coinfected outcome.
Auteur(s) : A BA, FK NDIAYE, YJ DJENG, C CAMES, A DIACK, O NDIAYE.
Pages : 131-137
Année de publication : 2018
Revue : International Journal of maternal Child Health and AIDS. 2018;8(2):131-137
N° de volume : 8(2):
Type : Article
Mise en ligne par : BA Abou